Phase 2 Study of Dacomitinib in NSCLC

NCT04027647 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

118

Enrollment

OTHER

Sponsor class

Conditions

NSCLC Stage IIIB
NSCLC Stage IIIC
NSCLC Stage IV
Recurrent NSCLC
EGFR Positive Non-Small Cell Lung Cancer

Interventions

DRUG: Dacomitinib

Sponsor

National Cancer Centre, Singapore

Collaborators

[object Object]